

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials [Erratum]

Hamed K, Wiktorowicz T, Assadi Gehr M. *Infect Drug Resist.* 2020;13:3209—3215.

The authors have advised that the Funding statement was missing on page 3214 of the published paper. This error was introduced by the Editorial staff during the publication process. The funding statement should read as follows:

Funding

The TARGET and ERADICATE trials were supported in part with federal funds from the Department of

Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600002C; and in part by Basilea Pharmaceutica International Ltd., Basel, Switzerland. BPR-PIP-002 trial was funded by Basilea Pharmaceutica International Ltd., Basel, Switzerland.

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>